General Atlantic to invest USD 100 mn in Rubicon ResearchIllustrative image – not actual.
Private equity firm General Atlantic will make an investment of USD 100 million in Rubicon Research, the pharmaceutical product development company in which it acquired a controlling stake recently. 

Rubicon Research plans to use the money to bring to market innovative medicines using its proprietary drug delivery technologies and expand manufacturing across the world.

With General Atlantic's growth focus, capital resources, strategic outlook and global connectivity, Rubicon Research will be able to accelerate its growth through organic and inorganic efforts.

Grow Together is a platform through which Rubicon Research will back, with both capital and strategic support, seed and early-stage ventures in the traditional pharmaceutical domain as well as allied domains involving the application of emerging technologies like artificial intelligence, continuous manufacturing and big data in the pharmaceutical industry.

General Atlantic will work with Rubicon Research on a number of strategic initiatives, including inorganic growth and geographic expansion of the company’s existing footprint.

← All latest storiesBack to top →